Abstract 5306
Background
The etiologic role of human papillomavirus (HPV) in oropharyngeal cancer (OPC) is well established and it explains the increase of young patients (pts) affected with OPC. This is an observational study representing a real-world experience evaluating clinicopathologic features and prognosis in young (<45 years old) OPC pts compared with older ones (≥45).
Methods
We conducted a retrospective cohort study of pts diagnosed with OPC in four Catalonian hospitals from 1991 to 2017. Data was collected from medical records. Unconditional logistic regression was used to compare age groups and Proportional hazards model (Cox regression) and Cumulative Incident Function (CIF) to analyze OPC-specific survival (OPC-sS) in locally advanced cases.
Results
A total of 865 pts were included, 49 in the young group (median age 42; range 28.5-45.0) and 816 in the old group (median age 61; range 45.1-93.9). There were no differences between age groups in terms of sex, anatomic subsite, toxic habits, HPV status (positivity defined as double p16/DNA positivity) or stage at diagnosis. There were more non-smokers HPV-related (HPV+) OPC pts than HPV-negative (HPV-) ones (p-value <0.001) in both age groups. Median follow-up was 2.24 years (0-22). Trend test showed that HPV+ OPC in the young group increased with time period but the proportion of young pts decreased (p-values = 0.034 and 0.027, respectively). In terms OPC-sS women (HR 0.62, 95%CI 0.41-0.93) had better prognosis compared to men. In contrast, smoker and drinker pts had worse prognosis estimates (HR 1.68 [95%CI 1.13-2.51] and HR 1.77 [95%CI 1.26-2.48], respectively) compared to non-smoker and non-drinker pts. In the restricted analysis for the young pts these differences did not reach the significance. No differences in the OPC-sS were observed by age group (HR 0.78 [95%CI 0.49-1.25]). CIF showed better OPC-sS in HPV+ OPC pts compared to HPV- ones, independently of the age. No differences by age were observed in the restricted analysis for HPV+ OPC pts. Nevertheless, none of the young HPV+ OPC pts died in the follow-up compared with a 16.4% of cancer-related deaths in the HPV+ old group.
Conclusions
HPV is the most important prognostic factor in OPC independent of age.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ICO (Catalan Institute of Oncology).
Funding
The Instituto de Salud Carlos III-ISCIII (Spanish Government) co funded by EDER funds/ European Regional Development Fund (ERDF) - a way to build Europe (References: PI1102096, PI1401918, PI1500500, PI1501205, RD12/0036/0056, CIBERESP, CIBERONC).
Disclosure
M. Nieva: Travel / Accommodation / Expenses: Takeda; Travel / Accommodation / Expenses: Merck. S. Tous: Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK.: GSK; Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK.: Seegene; Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK.: Merck. M. Mena: Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK: GSK; Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK: Merck; Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK: Seegene. R. Mesia Nin: Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy: AZ; Advisory / Consultancy: Roche; Advisory / Consultancy: Nanobiotix. L. Alemany: Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK: GSK; Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK: Seegene; Research grant / Funding (institution), Cancer Epidemiology Research Program (ST LA MM) has received sponsorship for grants from Merck and co, Seegene and GSK: Merck. M. Taberna: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AZ; Advisory / Consultancy: Nanobiotics; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Bristol Myers. All other authors have declared no conflicts of interest.
Resources from the same session
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract
3186 - The landscape of immuno-oncology clinical trials in China
Presenter: Dawei Wu
Session: Poster Display session 3
Resources:
Abstract
3468 - Clinical Significance of Immune-related Creatine Phosphokinase Increase Associated with Anti PD1/PD-L1 immunotherapies.
Presenter: Samia Hajem
Session: Poster Display session 3
Resources:
Abstract
3836 - Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy
Presenter: Wim Meer
Session: Poster Display session 3
Resources:
Abstract
1343 - Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors
Presenter: Thura Win Htut
Session: Poster Display session 3
Resources:
Abstract
5783 - Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: a meta-analysis of 8,730 patients from clinical trials
Presenter: Guru Sonpavde
Session: Poster Display session 3
Resources:
Abstract
5422 - EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy
Presenter: Marie Kostine
Session: Poster Display session 3
Resources:
Abstract
1202 - Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)
Presenter: Shinichi Sasaki
Session: Poster Display session 3
Resources:
Abstract
2749 - Use of Checkpoint Inhibitors (CPI) in Allogeneic Stem Cell Transplant Recipients: An Institutional Experience and A Systemic Review of the Literature
Presenter: Chantal Saberian
Session: Poster Display session 3
Resources:
Abstract
3256 - Deep Learning Radiomics distinguishes intrapulmonary Disease from Metastases in Immunotherapy-treated Melanoma Patients
Presenter: Thi Dan Linh Nguyen-Kim
Session: Poster Display session 3
Resources:
Abstract